Moteur de recherche d’entreprises européennes
Financement de l’UE (8 000 000 €) : Toxicologie translationnelle quantitative des systèmes pour améliorer la compréhension de la sécurité des médicaments - Sofia : 116030 Hor01/01/2017 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Toxicologie translationnelle quantitative des systèmes pour améliorer la compréhension de la sécurité des médicaments - Sofia : 116030
TransQST will develop a Quantitative Systems Toxicology (QST) approach, employing pre-existing data where possible, in order to yield new mechanistic insight into drug-induced toxicity. A central tenet of our programme will be to ensure the human physiological and pharmacological relevance of any test system that has been (or will be) used for generating the input data for modelling. By adopting this approach, we will be able to accurately interpret what happens when test systems are perturbed by drug exposure, and ensure translatability of modelling tools. Mechanistic translational biomarkers are a core aspect of our approach and will be applied in parallel with evidence for understanding how to develop, model and apply such biomarkers in a QST setting. The project is structured in 8 work packages to provide the following outcomes: curate the best available experimental data suitable for modelling adverse drug reactions; provide fit-for-purpose QST models that will address key toxicity measures for liver, kidney, heart and GI-tract; provide quantitative risk assessment for off-target toxicity in man based on in vitro and in vivo models; provide a quantitative mechanistic read-across from species (in vivo and in vitro) currently used for the toxicological evaluation of a new drug; provide definition and applicability of the human physiological relevance of preclinical test systems; provide a battery of translational biomarkers that can be used for quantitative read-across from in vitro systems to man and which relate to intracellular pathways (and systems) relevant to drug toxicity. Led by the University of Liverpool, TransQST brings together 14 partners, characterized by their scientific rigour and proven track record. Collectively they will enable achievement of the goals of the call, thanks to their complementarity, proven ability to work together (and with EFPIA partners), and their understanding of how to ensure the relevance of QST to human biology.
| ABBVIE DEUTSCHLAND GmbH & Co. KG | 0,00 € |
| Astrazeneca AB | 0,00 € |
| 0,00 € | |
| Certara UK Ltd. | 484 600 € |
| 325 354 € | |
| 1 093 089 € | |
| Eli Lilly and Company Ltd. | 0,00 € |
| Erasmus Universitair Medisch Centrum Rotterdam | 220 500 € |
| 350 250 € | |
| Fundacio Institut Hospital del Mar D Investigacions Mediques | 900 525 € |
| 0,00 € | |
| Institut de Recherches Internationales Servier Iris | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| ORION Oyj | 0,00 € |
| Sanofi-Aventis Recherche & Developpement | 0,00 € |
| Synapse Research Management Partners SL | 353 669 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 325 000 € |
| The University of Liverpool | 1 161 914 € |
| UNIVERSITAETSKLINIKUM AACHEN | 132 435 € |
| UNIVERSITATSKLINIKUM HEIDELBERG | 269 790 € |
| Universitat Wien | 350 250 € |
| Universiteit Leiden | 1 239 324 € |
| Universiteit Maastricht | 793 300 € |
| Vertex Pharmaceuticals (Europe) Ltd. | 0,00 € |
https://cordis.europa.eu/project/id/116030
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "ABBVIE DEUTSCHLAND GmbH & Co. KG - Financement de l’UE (8 000 000 €) : Toxicologie translationnelle quantitative des systèmes pour améliorer la compréhension de la sécurité des médicaments - Sofia : 116030"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
